AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

592.490

+0.4710.08%

Number of Gainers:14

Number of Losers:14

Number of Flat:17

PE:- -

High:597.258

Open:593.703

Low:587.469

Close:592.019

Volume:91.70M

Turnover:170.86M

Market Cap:81.39B

Float Cap:78.40B

Loading ...

Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives

Simply Wall St.

BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million

BRIEF-Cann Group Posts Profit For Half-Year A$26.4 Million

BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales

Cann Group Ltd - Revenue From Ordinary Activities a$4.5 Mln for Hy

THOMSON REUTERS

Cann Group - Profit for Half-Year a$26.4 Mln

THOMSON REUTERS

Botanix Pharmaceuticals Ltd - Revenue From Ordinary Activities for Hy a$16.5 Mln

THOMSON REUTERS

Polynovo Ltd-Change of Director's Interest Notice

THOMSON REUTERS

Mesoblast Posts HY Total Revenues $51.3 Million

ASX Biggest Losers

MT Newswires Live

BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million

BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million

BRIEF-Actinogen Medical Completes A$16.8M Placement And Spp

Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x

Ryoncil® Profits Underpinning Substantial Growth Pipeline

THOMSON REUTERS

Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline

Anagenics Ltd-Change of Director's Interest Notice

THOMSON REUTERS

Actinogen Medical Ltd - Completes a$16.8M Placement and Spp

THOMSON REUTERS

Mesoblast Ltd - Sees Full-Year Fiscal 2026 Ryoncil Net Revenue to Range Between US$110 Million and US$120 Million

THOMSON REUTERS

Mesoblast Ltd - Hy Total Revenues $51.3 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":592.4896,"timestamp":1772168399911,"preClose":592.0187,"halted":0,"volume":91701236,"delay":0,"changeRate":0.000795,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.470947,"latestTime":"02-27 16:00:00 AEDT","open":593.7034,"high":597.2581,"low":587.4691,"amount":170861640,"amplitude":0.016535,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772406000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1772146800000,1772168400000]],"turnoverRate":0.003522,"increases":13,"decrements":14,"flats":17,"marketCap":81385318361.75,"floatMarketCap":78397802434.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":597.2581,"amplitude":0.016535,"preClose":592.0187,"low":587.4691,"latestPrice":592.4896,"volume":91701236,"delay":0,"open":593.7034,"prevYearClose":644.3692,"prevWeekClose":619.951,"prevMonthClose":674.161,"prevQuarterClose":644.369,"fiveDayClose":619.951,"twentyDayClose":674.161,"sixtyDayClose":670.922,"secType":"PLATE","market":"AU","turnoverRate":0.003522,"marketCap":81385318361.75,"floatMarketCap":78397802434.75,"timestamp":1772168399911,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":14,"down":14,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614858228","title":"Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858228","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858228?lang=en_us&edition=fundamental","pubTime":"2026-02-27 16:43","pubTimestamp":1772181827,"startTime":"0","endTime":"0","summary":"Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4099","BK7508","BK7067","ACW.AU","TTM","BK4523"],"gpt_icon":0},{"id":"2614072882","title":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614072882","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614072882?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:57","pubTimestamp":1772179062,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 MillionFeb 27 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:HY LOSS ATTRIBUTABLE A$33.2 MILLIONREVENUE FROM ORDINARY ACTIVITIES FOR HY A$16.5 MILLIONFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BOT.AU","BK7502","BK7096"],"gpt_icon":0},{"id":"2614888242","title":"BRIEF-Cann Group Posts Profit For Half-Year A$26.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614888242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614888242?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:50","pubTimestamp":1772178627,"startTime":"0","endTime":"0","summary":"BRIEF-Cann Group Posts Profit For Half-Year A$26.4 MillionFeb 27 (Reuters) - Cann Group Ltd CAN.AX:PROFIT FOR HALF-YEAR A$26.4 MILLIONREVENUE FROM ORDINARY ACTIVITIES A$4.5 MILLION FOR HYFurther company coverage: CAN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7502","CAN.AU","BK7096"],"gpt_icon":0},{"id":"2614288815","title":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2614288815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614288815?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:54","pubTimestamp":1772168074,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales** Shares of drug maker Clinuvel Pharmaceuticals CUV.AX slip as much as 8.24% to A$10.130, lowest since July 8, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL6N3ZN0AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2614888589","title":"Cann Group Ltd - Revenue From Ordinary Activities a$4.5 Mln for Hy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614888589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614888589?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:42","pubTimestamp":1772167352,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2CU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CAN.AU","BK7502","BK7096","BK7508"],"gpt_icon":0},{"id":"2614885868","title":"Cann Group  - Profit for Half-Year a$26.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614885868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614885868?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:42","pubTimestamp":1772167352,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CAN.AU","BK7502","BK7096","BK7508"],"gpt_icon":0},{"id":"2614000023","title":"Botanix Pharmaceuticals Ltd - Revenue From Ordinary Activities for Hy a$16.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614000023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614000023?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:21","pubTimestamp":1772166100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2A8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BOT.AU","BK7502","BK7508"],"gpt_icon":0},{"id":"2614004368","title":"Polynovo Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2614004368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614004368?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:33","pubTimestamp":1772159603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUE93XGFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","BK7508","PNV.AU"],"gpt_icon":0},{"id":"2614001990","title":"Mesoblast Posts HY Total Revenues $51.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001990","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001990?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:13","pubTimestamp":1772158413,"startTime":"0","endTime":"0","summary":"Feb 27 (Reuters) - Mesoblast Ltd ::*HY TOTAL REVENUES $51.3 MILLION*HY LOSS ATTRIBUTABLE $40.2 MILLION*Further company coverage: MSB.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-FEB-202602:03:10 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nRSD2kTnKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2614001368","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001368?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:02","pubTimestamp":1772157763,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Friday.Coles Group : -9%, AU$20.12Liontown : -7%, AU$1.6850Harvey Norman Holdings : -7%, AU$5.86Worley : -6%, AU$10.95Mesoblast : -6%, AU$2.27IGO : -4%, AU$8.53NEXTDC : -4%, AU$13.72TPG Telecom : -4%, AU$3.89Perenti : -3%, AU$2.3550Genesis Energy  : -3%, AU$1.96","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7043","MSB.AU","COL.AU","BK7040","BK7042","BK7067","IGO.AU","WOR.AU","GNE.AU","TPG.AU","HVN.AU","BK7501","BK7503","BK7108","BK7095","BK7507","PRN.AU","BK7041","BK7082","BK7055","BK7153","BK7506","LTR.AU","BK7508","NXT.AU","BK7504","BK7006"],"gpt_icon":0},{"id":"2614967009","title":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614967009","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614967009?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:48","pubTimestamp":1772156885,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 MillionFeb 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:HY NET LOSS ATTRIBUTABLE A$23.2 MILLIONHY  REVENUE FROM CONTINUING ACTIVITIES A$284,055Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM26V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2614009566","title":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009566","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614009566?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:41","pubTimestamp":1772156490,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 MillionFeb 27  - Mesoblast Ltd MSB.AX:SEES FULL-YEAR FISCAL 2026  RYONCIL NET REVENUE TO RANGE BETWEEN  US$110 MILLION AND US$120 MILLIONFurther company coverage: MSB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7501","BK7508","BK7067","MESO","MSB.AU"],"gpt_icon":0},{"id":"2614900988","title":"BRIEF-Actinogen Medical Completes A$16.8M Placement And Spp","url":"https://stock-news.laohu8.com/highlight/detail?id=2614900988","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614900988?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:39","pubTimestamp":1772156345,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Completes A$16.8M Placement And SppFeb 27 (Reuters) - Actinogen Medical Ltd ACW.AX:COMPLETES A$16.8M PLACEMENT AND SPPFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM27G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2614005300","title":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005300","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005300?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:43","pubTimestamp":1772153001,"startTime":"0","endTime":"0","summary":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x               Mesoblast (MESO) reported H1 FY2026 total revenue of USD 51.3 million, up from USD 3.2 million, driven by the U.S. commercial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7Jkf4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","MSB.AU","BK7067","SG9999014005.SGD","LU2210149790.SGD","SG9999014013.SGD","BK7508","SG9999014039.USD","BK4588","BK4112","BK7501","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD"],"gpt_icon":0},{"id":"2614053220","title":"Ryoncil® Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614053220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614053220?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152974,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA6XZHMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2614005533","title":"Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005533?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152920,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 26, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 .Performance driven by successful commercial launch of Ryoncil. -- Total revenue of US$51.3 million ,2 up from US$3.2. generated gross sales of US$57.0 million and revenue of US$48.7 million. -- Ryoncil gross profit, excluding amortization, was US$44.2 million. versus nil in the prior year period. Direct selling costs were US$7.7. -- The strong operating performance in the period allowed us to invest in. R&D, including to support the Phase 3 trial on the blockbuster chronic. -- Reported net loss of US$40.2 million compared to US$47.9 million, an. improvement of US$7.8 million. Excluding a US$23.0 million inventory. -- Net operating cash spend of US$30.3 million. Mesoblast expects to see. -- Period-end cash balance of US$130.0 million. Mesoblast entered into a. US$125.0 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MESO","LU0661504455.SGD","LU1003077747.HKD","MSB.AU","BK7501","BK4208","BK7067","CMS","LU2346227817.USD","R","LU2637428348.USD","MSC","LU2500361329.USD","LU0949170772.SGD","BK4139","BK4232","LU0553294199.USD","BK4585","BK4575","BK7508","BK4022","LU1894683264.USD","LU0738911758.USD","BK4588","LU1894683348.USD","LU0545039389.USD"],"gpt_icon":0},{"id":"2614070963","title":"Anagenics Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2614070963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614070963?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:29","pubTimestamp":1772148575,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUE7BXKJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AN1.AU","BK7111","BK7508"],"gpt_icon":0},{"id":"2614724410","title":"Actinogen Medical Ltd -  Completes a$16.8M Placement and Spp","url":"https://stock-news.laohu8.com/highlight/detail?id=2614724410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614724410?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:34","pubTimestamp":1772145263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM27G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2614717700","title":"Mesoblast Ltd - Sees Full-Year Fiscal 2026  Ryoncil Net Revenue to Range Between  US$110 Million and US$120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614717700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614717700?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:50","pubTimestamp":1772142640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK4139","BK7067","MSB.AU","MESO"],"gpt_icon":0},{"id":"2614071169","title":"Mesoblast Ltd - Hy Total Revenues $51.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071169?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:44","pubTimestamp":1772142247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MSB.AU","BK4139","BK7501","MESO","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":99,"code":"91000000","status":"200"}]}}